Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Adverse Drug Reactions in Corona Virus Disease Patients Admitted to Intensive Care Unit: An Observational Study

Author(s): Nazia Nazir, Deepti Chopra*, Bharti Bhandari and Jaspreet Kaur Sidhu

Volume 18, Issue 2, 2023

Published on: 05 August, 2022

Page: [202 - 206] Pages: 5

DOI: 10.2174/1574886317666220513095618

Price: $65

Abstract

Background: Occurrence of adverse drug reactions (ADRs) in COVID-19 patients has not been extensively studied.

Aim: The present study was conducted to analyze the pattern of suspected ADRs in the COVID-19 Intensive Care Unit (ICU).

Methods: In this cross-sectional study, all the individual case study reports of patients admitted to the COVID ICU (August-October 2020) were analyzed for type of ADRs, system involved, suspected drug, onset time, time to revert and management.

Results: Thirty six patients (out of 395 patients admitted) experienced 44 ADRs. Dermatological manifestations were the most frequent ADRs. Remdesivir was the most common drug associated with ADRs. The female gender, polypharmacy (>5 drugs) and presence of comorbidities were the independent risk factors for the occurrence of ADRs.

Conclusion: Use of many of these drugs in COVID-19 is experimental and the literature does not guarantee their safety and efficacy. During these times of uncertainty, the results from the present study reinforce the importance of monitoring patients.

Keywords: ADR, COVID-19, ICU, monitoring, safety, pharmacovigilance.

« Previous Next »
[1]
Clinical guidance for management of adult COVID-19 patients. In. Available from: https://www.icmr.gov.in/pdf/covid/techdoc/COVID_Management_ 14012022.pdf [Accessed on 18th Apr 2022].
[2]
Moore P, Burkhart K. Adverse Drug Reactions in the Intensive Care Unit. In: Brent J, Bukhart K, Dargan P, Eds. Critical Care Toxicology. 2017.
[http://dx.doi.org/10.1007/978-3-319-17900-1_33]
[3]
Joshua L, Devi P, Guido S. Adverse drug reactions in medical intensive care unit of a tertiary care hospital. Pharmacoepidemiol Drug Saf 2009; 18(7): 639-45.
[http://dx.doi.org/10.1002/pds.1761] [PMID: 19421963]
[4]
Ramírez E, Urroz M, Rodríguez A, et al. Incidence of suspected serious adverse drug reactions in corona virus disease-19 patients detected by a pharmacovigilance program by laboratory signals in a tertiary hospital in Spain: Cautionary data. Front Pharmacol 2020; 11: 602841.
[http://dx.doi.org/10.3389/fphar.2020.602841] [PMID: 33343374]
[5]
World Health Organization. The Uppsala Monitoring Centre. The use of the WHO-UMC system for standardised case causality assessment 2018. 2021. Available from: https://www.who.int/medicines/areas/quality_safety/safety_efficacy/WHOcausality_assessment.pdf [Accessed on 18th Apr 2022].
[6]
Safety of Medicines. 2021. Available from: http://www. whqlibdoc.who.int/hq/2002/.WHO_EDM_QSM_ [Accessed on 18th Apr 2022].
[7]
Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm 1992; 49(9): 2229-32.
[http://dx.doi.org/10.1093/ajhp/49.9.2229] [PMID: 1524068]
[8]
Sun J, Deng X, Chen X, et al. Incidence of adverse drug reactions in COVID-19 patients in China: An active monitoring study by hospital pharmacovigilance system. Clin Pharmacol Ther 2020; 108(4): 791-7.
[http://dx.doi.org/10.1002/cpt.1866] [PMID: 32324898]
[9]
Melo JRR, Duarte EC, Moraes MV, Fleck K, Silva ASDNE, Arrais PSD. Adverse drug reactions in patients with COVID-19 in Brazil: Analysis of spontaneous notifications of the Brazilian pharmacovigilance system. Cad Saude Publica 2021; 37(1): e00245820.
[http://dx.doi.org/10.1590/0102-311x00245820] [PMID: 33503163]
[10]
Pedrós C, Quintana B, Rebolledo M, Porta N, Vallano A, Arnau JM. Prevalence, risk factors and main features of adverse drug reactions leading to hospital admission. Eur J Clin Pharmacol 2014; 70(3): 361-7.
[http://dx.doi.org/10.1007/s00228-013-1630-5] [PMID: 24362489]
[11]
Lavan AH, Gallagher P. Predicting risk of adverse drug reactions in older adults. Ther Adv Drug Saf 2016; 7(1): 11-22.
[http://dx.doi.org/10.1177/2042098615615472] [PMID: 26834959]
[12]
Zekarias A, Watson S, Vidlin SH, Grundmark B. Sex differences in reported adverse drug reactions to COVID-19 drugs in a global data-base of individual case safety reports. Drug Saf 2020; 43(12): 1309-14.
[http://dx.doi.org/10.1007/s40264-020-01000-8] [PMID: 32978702]
[13]
Kojima T, Matsui T, Suzuki Y, et al. Risk factors for adverse drug reactions in older inpatients of geriatric wards at admission: Multicenter study. Geriatr Gerontol Int 2020; 20(2): 144-9.
[http://dx.doi.org/10.1111/ggi.13844] [PMID: 31829506]
[14]
Bassi PU, Osakwe AI, Ogar CK, et al. Impact of comorbidity on adverse drug reaction profile in a cohort of patients treated with Artemisinin combination therapies for uncomplicated malaria in Nigeria. Pharmacol Res Perspect 2017; 5(2): e00302.
[http://dx.doi.org/10.1002/prp2.302] [PMID: 28357128]
[15]
Crescioli G, Brilli V, Lanzi C, et al. Adverse drug reactions in SARS-CoV-2 hospitalised patients: A case-series with a focus on drug-drug interactions. Intern Emerg Med 2021; 16(3): 697-710.
[http://dx.doi.org/10.1007/s11739-020-02586-8] [PMID: 33355896]
[16]
Chouchana L, Preta LH, Tisseyre M, Terrier B, Treluyer JM, Montastruc F. Kidney disorders as serious adverse drug reactions of remdesivir in coronavirus disease 2019: A retrospective case-noncase study. Kidney Int 2021; 99(5): 1235-6.
[http://dx.doi.org/10.1016/j.kint.2021.02.015] [PMID: 33647327]
[17]
Najar Nobari N, Seirafianpour F, Mashayekhi F, Goodarzi A. A systematic review on treatment-related mucocutaneous reactions in COVID-19 patients. Dermatol Ther 2021; 34(1): e14662.
[http://dx.doi.org/10.1111/dth.14662] [PMID: 33301232]

Rights & Permissions Print Cite
Article Metrics
3
© 2024 Bentham Science Publishers | Privacy Policy